If the closeness you once felt has quietly changed since menopause, you are not imagining it, and wanting that closeness back at any age is entirely normal. One question that comes up often for women exploring low-dose testosterone is deceptively practical: how the medication is delivered, and why that choice differs so much from a man's protocol.
Why testosterone is part of the women's conversation at all
Testosterone is often labeled a "male hormone," but women make it too, and levels decline gradually with age. Research and clinical guidance now recognize a specific, narrow role for testosterone in women: a global consensus position statement from several major endocrine and menopause societies concluded that the only evidence-based use of testosterone in women is for hypoactive sexual desire dysfunction (HSDD) in post-menopausal women, after other contributing factors have been considered [1].
That last part matters. Desire is rarely one thing. Sleep, stress, relationship dynamics, mood, medications, vaginal comfort, and estrogen status can all play a role. A careful independent provider treats "my desire faded" as a starting point for a conversation and labs, not a diagnosis to rush. So if you have wondered whether this is hormones, stress, or your relationship, the honest answer is that it can be several at once, and sorting that out is exactly what the review process is for.
This article is educational and is not medical advice. Whether any therapy is appropriate is a decision an independent, licensed provider makes with you.
Source: [1] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
The core difference from a man's protocol: the dose is small
The single most important framing point is scale. Testosterone therapy in women aims to restore concentrations to the normal premenopausal physiologic range, not to raise them beyond it [1]. Male testosterone dosing operates at a completely different order of magnitude. Because of that, the delivery format question for women is really a question about precision: how do you deliver a small, steady amount without overshooting?
That is also why the consensus guidance specifically cautions against male-formulated products used off-label in women, and against pellets and injections, largely because they can produce supraphysiologic (higher than normal) levels that are hard to fine-tune [1]. Understanding that helps explain why a provider may frame the formats differently than you might expect.
relative testosterone level · marker = Therapy target
Source: [1] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
How a provider weighs cream, pellet, and compounded
Here is the practical landscape, described in general educational terms. None of this is a recommendation, and a provider will individualize based on your history and labs.
Topical cream or gel
Transdermal (through-the-skin) delivery is the format most aligned with the global consensus preference, because it delivers small daily amounts and allows adjustment [1]. The tradeoffs a provider weighs include absorption that can vary from person to person, and the need to avoid skin-to-skin transfer to a partner or others. Because there is currently no testosterone product formulated and approved specifically for women in the United States, providers often work with either off-label use of an approved male product at a reduced amount or a compounded preparation [1][2].
Pellets
Subcutaneous pellets are implanted and release testosterone over months. The appeal is convenience. The concern that leads major guidance to advise against them is control: once placed, the dose cannot be adjusted, and studies have documented supraphysiologic levels with pelleted testosterone in women [1]. A provider focused on staying within the physiologic range may view this format cautiously for that reason.
Compounded formulations
Because no female-specific product is FDA-approved, some preparations for women are compounded by a licensed pharmacy to a provider's specifications. Compounding can allow lower, tailored concentrations. It also comes with an important honesty: compounded products are not FDA-reviewed.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Absorption and monitoring: what actually gets checked
Because the target is a narrow range, monitoring is central rather than optional. A provider typically establishes a baseline and then rechecks to confirm levels have not risen above the normal female physiologic range [1]. Guidance emphasizes measuring total testosterone with reliable assays and avoiding overtreatment.
One useful biomarker context: much of circulating testosterone is bound to a protein called sex hormone-binding globulin (SHBG), and only a small unbound fraction is biologically active. SHBG can shift with estrogen therapy, thyroid status, and other factors, which is one reason interpretation belongs with a provider and a lab, not a home guess [3].
Safety review over time generally includes watching for androgenic effects (such as acne or unwanted hair changes), and the consensus statement notes that at physiologic doses, evidence has not shown serious adverse effects, while long-term data (including cardiovascular and breast safety beyond about 24 months) remain limited [1]. That limitation is precisely why ongoing provider oversight, rather than a set-it-and-forget-it approach, is the norm.
Source: [1] Global Consensus Position Statement on the Use of Testosterone Therapy for Women, [3] MedlinePlus: Sex Hormone Binding Globulin (SHBG) Test
Desire is not only about one molecule
For many post-menopausal women, physical comfort during intimacy is driven substantially by the drop in estrogen, which affects vaginal tissue. This is distinct from desire, and it is common for both to change at once [4]. A thoughtful provider looks at the whole picture, because addressing comfort and addressing desire are not the same task, and testosterone is only one possible piece of a broader conversation.
It is also worth saying plainly: wanting to feel close to your partner is not a problem to apologize for. It is a health and quality-of-life question that clinicians take seriously, and you deserve to be spoken to like the intelligent adult you are.
Questions you can bring to a visit
- What could be driving the change for me specifically: hormones, medications, comfort, stress, or a combination?
- What would my labs need to show before any therapy is even considered?
- If a therapy were appropriate, which delivery format fits the goal of staying in the normal range, and how would we monitor it?
- What are the known and unknown risks over time?
Bringing questions like these turns an awkward topic into an ordinary medical conversation, which is exactly what it should be.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri does not practice medicine and does not guarantee any prescription. What Velri can do is coordinate the pieces: help arrange appropriate lab work, connect you with an independent, physician-led Provider Group for an evaluation, and, if an independent licensed provider determines a therapy is appropriate for you, coordinate with an independent licensed pharmacy for fulfillment. Any decision about testosterone therapy, including whether it is suitable and in what form, rests entirely with the independent provider.
Coverage currently starts in Nevada, with more states rolling out over time.
This article is educational and is not medical advice. Please talk with a licensed clinician about your individual situation.
